# Syntimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syntimmune

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.syntimmune.com
- Total disclosed funding: $76M
- Latest round: Series B (Jun 21, 2017)
- Investors on record: 4

## About

Syntimmune, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic solutions targeting complement-mediated diseases through innovative antibody treatments.Founded in 2013 and headquartered in Boston, US, Syntimmune, Inc. specializes in developing therapies for complement-mediated disorders. In September 2018, it was acquired by Alexion Pharmaceuticals, Inc. for an upfront payment of USD 400 mn, with potential milestone payments up to USD 800 mn, totaling up to USD 1.2 bn. The company's operations and strategic focus have remained aligned with Alexion's objectives following the acquisition.Syntimmune, Inc. focuses on developing innovative therapies for patients with complement-mediated disorders, particularly through monoclonal antibodies. The company’s products are designed to address conditions involving the immune system's complement pathway, providing targeted treatment options for various diseases.Syntimmune, Inc. generates revenue through the development of its therapeutic products, particularly those related to complement-mediated diseases. Following its acquisition by Alexion Pharmaceuticals, the revenue structure has shifted to align with Alexion's sales channels and distribution strategies, ensuring a streamlined approach to market entry for its therapies.With the acquisition by Alexion Pharmaceuticals, Syntimmune, Inc. is positioned to leverage Alexion's infrastructure for broader market penetration. Upcoming initiatives include the development of new products that expand treatment options for patients with rare diseases. The acquisition funding will be utilized to enhance research and development activities aimed at launching these innovative therapies. Alexion plans to utilize Syntimmune's expertise to explore new markets, particularly in Europe and Asia by 2021, addressing the unmet medical needs in these regions.

## Funding rounds

- Series B, Jun 21, 2017, $50M — Apple Tree Partners, Mass General Brigham Ventures, Baxalta Ventures
- Series A, Nov 17, 2016, $8M — Apple Tree Partners, Baxalta Ventures, Innovation Fund
- Series A, Mar 22, 2016, $10M — Apple Tree Partners, Mass General Brigham Ventures, Baxalta Ventures
- Series A, Oct 14, 2014, $8M — Apple Tree Partners, Baxalta Ventures

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A, Series B
- Baxalta Ventures (https://capitalatlas.ai/funds/baxalta-ventures) — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Innovation Fund (https://capitalatlas.ai/funds/innovation-fund) — Series A